公开(公告)号：US09526776B2

公开(公告)日：2016-12-27

申请号：US14420238

申请日：2013-09-06

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Barbara Baudner ,  Derek O'Hagan ,  Manmohan Singh ,  Simone Bufali

IPC: A61K39/095 ,  A61K39/39 ,  A61K39/00

CPC classification number: A61K39/095 ,  A61K39/39 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/6037

Abstract: Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response which the composition elicits; alternatively, by including an adjuvant it is possible for the compositions to have a relatively lower amount of antigen while nevertheless having immunogenicity which is comparable to unadjuvanted combination vaccines.

Abstract translation: 血清群B脑膜炎球菌抗原可以成功地与白喉，破伤风和百日咳类毒素（“DTP”）结合，为防止多种病原体提供有效的组合疫苗。 这些组合对于一系列不同的佐剂是有效的，并且具有儿科型和增强型DTP比。 佐剂可以改善组合物引起的免疫反应; 或者，通过包括佐剂，组合物可能具有相对较低量的抗原，同时具有与未佐剂组合疫苗相当的免疫原性。

公开(公告)号：US20180280301A1

公开(公告)日：2018-10-04

申请号：US15981104

申请日：2018-05-16

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Derek O'Hagan ,  Manmohan Singh ,  Siddhartha Jain ,  Padma Malyala

IPC: A61K9/14 ,  A61K39/095 ,  A61J1/00 ,  A61K39/00

Abstract: In one aspect, the present invention provides sterile microparticle compositions comprising biodegradable microparticles, which comprise at least one biodegradable polymer. In other aspects, the present invention provides methods of making and using such compositions as well as articles of manufacture and kits containing the same.

公开(公告)号：US09931399B2

公开(公告)日：2018-04-03

申请号：US15163592

申请日：2016-05-24

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Barbara Baudner ,  Derek O'Hagan ,  Manmohan Singh ,  Simone Bufali

IPC: A61K39/00 ,  A61K39/39 ,  A61K9/107 ,  A61K39/13 ,  C12N7/00

CPC classification number: A61K39/39 ,  A61K9/107 ,  A61K39/0018 ,  A61K39/13 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55566 ,  A61K2039/55572 ,  C12N7/00 ,  C12N2770/32634 ,  Y02A50/466

Abstract: The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.